This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Dermavant Sciences, Inc.
Dermavant Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for dermatological conditions. Founded in 2014, Dermavant has rapidly established itself in the dermatology industry, with a commitment to addressing unmet medical needs through advanced research and development. The company’s core products include unique topical treatments that leverage cutting-edge science to enhance patient outcomes. Dermavant's flagship product, a novel formulation for psoriasis, exemplifies its dedication to delivering effective solutions that improve the quality of life for patients. With a strong market position, Dermavant has achieved significant milestones, including successful clinical trials and strategic partnerships that bolster its operational reach across North America and beyond. As a pioneer in dermatological innovation, Dermavant Sciences continues to shape the future of skin health.
DitchCarbon Score
How does Dermavant Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dermavant Sciences, Inc.'s score of 43 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dermavant Sciences, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Organon & Co., and any emissions data or climate commitments may be inherited from this parent organisation. As of now, Dermavant has not established any documented reduction targets or climate pledges. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. In the broader context, as a subsidiary of Organon & Co., Dermavant may align with the sustainability and climate commitments set forth by its parent company, which could include industry-standard practices and initiatives aimed at reducing carbon footprints. However, without explicit data or commitments from Dermavant itself, it is challenging to provide a detailed overview of its climate impact or goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dermavant Sciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
